Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544471 | 0.89 | CYP19A1 (0.40) | CYP19A1TGM2DRD4SIGMAR1 | |
| SCHEMBL15543953 | 0.87 | CYP19A1 (0.37) | CYP19A1TGM2DRD4SIGMAR1SLC5A1 | |
| SCHEMBL15545349 | 0.86 | BCHE (0.36) | CYP19A1DRD4SIGMAR1THRB | |
| SCHEMBL15607911 | 0.82 | CYP19A1 (0.40) | CYP19A1TGM2DRD4SIGMAR1SLC5A1 | |
| SCHEMBL16367401 | 0.82 | CYP19A1 (0.40) | CYP19A1TGM2DRD4SIGMAR1SLC5A1 | |
| SCHEMBL15544684 | 0.82 | PKM (0.37) | CYP19A1THRB | |
| SCHEMBL15545174 | 0.82 | THRB (0.32) | THRB | |
| SCHEMBL941576 | 0.81 | CYP3A4 (0.33) | CYP19A1THRB | |
| SCHEMBL15544095 | 0.81 | THRB (0.31) | THRB | |
| SCHEMBL15544218 | 0.80 | GUSB (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| EP-2793871-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | Auckland Uniservices Limited (NZ) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014007650-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | CYP19A1 442/4885TGM2 1258/4885DRD4 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.